Zacks Small Cap Comments on FibroBiologics, Inc.’s Q2 2024 Earnings (NASDAQ:FBLG)

FibroBiologics, Inc. (NASDAQ:FBLG) – Investment analysts at Zacks Small Cap issued their Q2 2024 earnings per share estimates for shares of FibroBiologics in a research report issued on Monday, June 24th. Zacks Small Cap analyst D. Bautz expects that the company will earn ($0.09) per share for the quarter. The consensus estimate for FibroBiologics’ current full-year earnings is ($0.47) per share. Zacks Small Cap also issued estimates for FibroBiologics’ Q3 2024 earnings at ($0.07) EPS, Q4 2024 earnings at ($0.07) EPS, FY2024 earnings at ($0.47) EPS, FY2025 earnings at ($0.29) EPS and FY2026 earnings at ($0.29) EPS.

FibroBiologics (NASDAQ:FBLG) last released its quarterly earnings data on Tuesday, May 14th. The company reported ($0.27) EPS for the quarter.

FibroBiologics Trading Up 3.8 %

NASDAQ:FBLG opened at $4.66 on Wednesday. The stock’s 50 day moving average price is $9.20. FibroBiologics has a 52-week low of $3.99 and a 52-week high of $55.00.

FibroBiologics Company Profile

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.